|
US6710174B2
(en)
|
2001-09-13 |
2004-03-23 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of vascular endothelial growth factor receptor-1 expression
|
|
US6100071A
(en)
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
|
US7070959B1
(en)
|
1999-06-08 |
2006-07-04 |
Regeneron Pharmaceuticals, Inc. |
Modified chimeric polypeptides with improved pharmacokinetic properties
|
|
US7087411B2
(en)
*
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
|
US6833349B2
(en)
*
|
1999-06-08 |
2004-12-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating inflammatory skin diseases
|
|
US7396664B2
(en)
|
1999-06-08 |
2008-07-08 |
Regeneron Pharmaceuticals, Inc. |
VEGF-binding fusion proteins and nucleic acids encoding the same
|
|
JP4669984B2
(ja)
|
2001-01-19 |
2011-04-13 |
ベジェニクス リミテッド |
腫瘍画像化のターゲットとしてのＦ１ｔ４（ＶＥＧＦＲ−３）および抗腫瘍療法
|
|
US6734017B2
(en)
|
2001-09-28 |
2004-05-11 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of vascular endothelial growth factor receptor-2 expression
|
|
WO2004108069A2
(en)
|
2002-05-04 |
2004-12-16 |
Acorda Therapeutics, Inc. |
Compositions and methods for promoting neuronal outgrowth
|
|
SI1608685T1
(sl)
|
2003-03-28 |
2007-08-31 |
Regeneron Pharma |
Antagonisti VEGF za zdravljenje diabetesa
|
|
MXPA05012307A
(es)
|
2003-05-16 |
2006-07-03 |
Acorda Therapeutics Inc |
Mutantes que degradan proteoglicanos para tratamiento del snc.
|
|
AU2004247025B8
(en)
*
|
2003-05-16 |
2011-06-30 |
Acorda Therapeutics, Inc. |
Fusion proteins for the treatment of CNS
|
|
US7959914B2
(en)
|
2003-05-16 |
2011-06-14 |
Acorda Therapeutics, Inc. |
Methods of reducing extravasation of inflammatory cells
|
|
AU2004242586C1
(en)
*
|
2003-05-28 |
2011-02-24 |
Regeneron Pharmaceuticals, Inc. |
Method of treating corneal transplant rejection by using VEGF antagonists
|
|
US7186699B2
(en)
|
2003-06-03 |
2007-03-06 |
Cell Genesys, Inc. |
Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
|
|
WO2004110490A2
(en)
*
|
2003-06-06 |
2004-12-23 |
Regeneron Pharmaceuticals, Inc. |
Use of vegf inhibitors for tumor regression
|
|
US7399612B2
(en)
|
2003-06-30 |
2008-07-15 |
Regeneron Pharmaceuticals, Inc. |
VEGF-binding fusion proteins and nucleic acids encoding the same
|
|
AR046510A1
(es)
|
2003-07-25 |
2005-12-14 |
Regeneron Pharma |
Composicion de un antagonista de vegf y un agente anti-proliferativo
|
|
WO2005016369A1
(en)
*
|
2003-08-06 |
2005-02-24 |
Regeneron Pharmaceuticals, Inc. |
Use of a vegf antagonist in combination with radiation therapy
|
|
AU2005244933B2
(en)
|
2004-05-18 |
2011-08-04 |
Acorda Therapeutics, Inc. |
Methods of purifying chondroitinase and stable formulations thereof
|
|
ATE548384T1
(de)
*
|
2004-06-08 |
2012-03-15 |
Chengdu Kanghong Biotechnologies Co Ltd |
Ein die angiogenese inhibierendes chimäres protein und dessen verwendung
|
|
AU2005254058A1
(en)
|
2004-06-10 |
2005-12-29 |
Regeneron Pharmaceuticals, Inc. |
Use of VEGF inhibitors for the treatment of human cancer
|
|
WO2006009809A2
(en)
*
|
2004-06-18 |
2006-01-26 |
Regeneron Pharmaceuticals, Inc. |
Vegf inhibitors for the treatment of malignant pleural effusion
|
|
JP4807802B2
(ja)
*
|
2004-07-30 |
2011-11-02 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｖｅｇｆ媒介性活性をブロックすることによるｉ型糖尿病を処置する方法
|
|
EP2229956B1
(en)
|
2004-09-13 |
2013-04-24 |
Genzyme Corporation |
Multimeric constructs
|
|
FR2878749B1
(fr)
*
|
2004-12-03 |
2007-12-21 |
Aventis Pharma Sa |
Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
|
|
WO2006088650A2
(en)
*
|
2005-02-02 |
2006-08-24 |
Regeneron Pharmaceuticals, Inc. |
Method of treating eye injury with local administration of a vegf inhibitor
|
|
CA2995971A1
(en)
|
2005-03-25 |
2006-10-05 |
Regeneron Pharmaceuticals, Inc. |
Vegf antagonist formulations
|
|
AU2006294755B2
(en)
|
2005-09-26 |
2012-04-19 |
Acorda Therapeutics, Inc. |
Compositions and methods of using chondroitinase ABCI mutants
|
|
JP5489465B2
(ja)
†
|
2005-12-16 |
2014-05-14 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｄｌｌ４アンタゴニストによって腫瘍増殖を阻害する治療方法
|
|
FR2895258B1
(fr)
|
2005-12-22 |
2008-03-21 |
Aventis Pharma Sa |
Combinaison comprenant de la combretastatine et des agents anticancereux
|
|
US8216575B2
(en)
|
2006-03-31 |
2012-07-10 |
Chengdu Kanghong Biotechnologies Co., Ltd. |
Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
|
|
CN100502945C
(zh)
*
|
2006-03-31 |
2009-06-24 |
成都康弘生物科技有限公司 |
Vegf受体融合蛋白在治疗眼睛疾病中的应用
|
|
AU2007261536C1
(en)
|
2006-06-16 |
2025-08-14 |
Regeneron Pharmaceuticals, Inc. |
VEGF antagonist formulations suitable for intravitreal administration
|
|
EP2066694B1
(en)
|
2006-09-29 |
2015-11-04 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for diagnosing and treating cancer
|
|
AU2007307736C1
(en)
|
2006-10-10 |
2014-04-10 |
Acorda Therapeutics, Inc. |
Compositions and methods of using chondroitinase ABCI mutants
|
|
FR2918279B1
(fr)
*
|
2007-07-05 |
2010-10-22 |
Aventis Pharma Sa |
Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
|
|
CN101575379B
(zh)
*
|
2008-05-09 |
2012-05-30 |
上海抗体药物国家工程研究中心有限公司 |
可溶性vegfr双功能融合受体、其制备方法及用途
|
|
MX359570B
(es)
|
2008-11-03 |
2018-10-01 |
Molecular Partners Ag |
Proteinas de union que inhiben la interaccion en el receptor de vegf-a.
|
|
CN101838329A
(zh)
*
|
2009-03-18 |
2010-09-22 |
嘉和生物药业有限公司 |
抗血管新生融合蛋白
|
|
PT2488204E
(pt)
|
2009-10-16 |
2016-06-09 |
Oncomed Pharm Inc |
Combinação terapêutica e utilização de anticorpos antagonistas de dll4 e agentes anti-hipertensivos
|
|
TWI510246B
(zh)
|
2010-04-30 |
2015-12-01 |
Molecular Partners Ag |
抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
|
|
HUE035554T2
(en)
|
2010-08-06 |
2018-05-02 |
Genzyme Corp |
VEGF antagonist compositions and their uses
|
|
JP6043629B2
(ja)
*
|
2011-01-07 |
2016-12-14 |
中外製薬株式会社 |
抗体の物性を改善させる方法
|
|
SG191334A1
(en)
|
2011-01-13 |
2013-08-30 |
Regeneron Pharma |
Use of a vegf antagonist to treat angiogenic eye disorders
|
|
JO3283B1
(ar)
|
2011-04-26 |
2018-09-16 |
Sanofi Sa |
تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
|
|
KR101397088B1
(ko)
|
2011-06-10 |
2014-05-19 |
강원대학교산학협력단 |
암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
|
|
JO3370B1
(ar)
*
|
2011-11-10 |
2019-03-13 |
Regeneron Pharma |
طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
|
|
WO2013082563A1
(en)
*
|
2011-12-01 |
2013-06-06 |
Protevobio, Inc. |
Protein inhibitors to complement and vegf pathways and methods of use thereof
|
|
CN103304668B
(zh)
*
|
2012-03-12 |
2015-10-28 |
江苏健德生物药业有限公司 |
Ultra-VEGF-trap免疫融合蛋白、其制备方法及其应用
|
|
DK2846836T3
(da)
|
2012-05-07 |
2019-11-11 |
Allergan Inc |
Fremgangsmåde til behandling af amd hos patienter, der er refraktære overfor anti-vegf-terapi
|
|
WO2014006113A1
(en)
|
2012-07-03 |
2014-01-09 |
Sanofi |
Method of treating cancer by effective amounts of aflibercept
|
|
AR093445A1
(es)
|
2012-11-14 |
2015-06-10 |
Regeneron Pharma |
Metodos para tratar el cancer de ovario con antagonistas de dll4
|
|
CA2901226C
(en)
|
2013-02-18 |
2020-11-17 |
Vegenics Pty Limited |
Vascular endothelial growth factor binding proteins
|
|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
|
CN104193828B
(zh)
*
|
2013-09-12 |
2017-04-05 |
北京韩美药品有限公司 |
同时阻断her2和vegfr信号通路的重组融合蛋白
|
|
HUE047910T2
(hu)
|
2013-11-05 |
2020-05-28 |
Allergan Inc |
Eljárás a szem állapotainak kezelésére anti-VEGF darpinnal
|
|
WO2015173260A1
(en)
|
2014-05-12 |
2015-11-19 |
Formycon Ag |
Pre-filled plastic syringe containing a vegf antagonist
|
|
HUE043951T2
(hu)
|
2014-07-18 |
2019-09-30 |
Sanofi Sa |
Eljárás rákgyanús beteg aflibercepttel történõ kezelése kimenetének elõrejelzésére
|
|
JP2016036322A
(ja)
*
|
2014-08-11 |
2016-03-22 |
日本化薬株式会社 |
血管新生因子と結合するキメラタンパク質
|
|
CN106999511A
(zh)
|
2014-12-11 |
2017-08-01 |
拜耳医药保健有限责任公司 |
具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗
|
|
GB201503453D0
(en)
|
2015-03-01 |
2015-04-15 |
Jain Arjun |
Endothelin-1"sponge"
|
|
TW202440903A
(zh)
|
2015-08-04 |
2024-10-16 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法（一）
|
|
WO2017046140A1
(en)
|
2015-09-18 |
2017-03-23 |
Bayer Pharma Aktiengesellschaft |
Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
|
|
KR101936049B1
(ko)
*
|
2015-10-15 |
2019-01-08 |
(주)알테오젠 |
IgG Fc 도메인을 가지는 융합 단백질의 생산방법
|
|
WO2017065559A1
(ko)
|
2015-10-15 |
2017-04-20 |
(주)알테오젠 |
Igg fc 도메인을 가지는 융합 단백질의 생산방법
|
|
BR112018009953B1
(pt)
|
2015-11-18 |
2024-03-05 |
Formycon Ag |
Seringa farmacêutica pré-preenchida esterilizada, e, kit
|
|
BR112018010005A2
(pt)
|
2015-11-18 |
2018-11-21 |
Formycon Ag |
seringa pré-carregada, e, kit
|
|
US11654046B2
(en)
|
2015-11-18 |
2023-05-23 |
Sio2 Medical Products, Inc. |
Pharmaceutical package for ophthalmic formulations
|
|
WO2017084616A1
(en)
*
|
2015-11-19 |
2017-05-26 |
Zhuhai Tairuishang Biopharm Ltd. |
Methods and compositions for binding vegf
|
|
PT3384049T
(pt)
|
2015-12-03 |
2023-08-18 |
Regeneron Pharma |
Método de associação de variantes genéticas com um resultado clínico em doentes que sofrem de degeneração macular relacionada à idade tratados com anti-vegf
|
|
JP6953433B2
(ja)
|
2016-01-26 |
2021-10-27 |
フォーマイコン アーゲーＦｏｒｍｙｃｏｎ Ａｇ |
Ｖｅｇｆアンタゴニストを含む液体医薬組成物および同医薬組成物を含有する充填済みシリンジ
|
|
US20190300607A1
(en)
|
2016-10-12 |
2019-10-03 |
Daiichi Sankyo Company, Limited |
Composition containing anti-robo4 antibody and other agents
|
|
EP3541365A1
(en)
|
2016-11-21 |
2019-09-25 |
Just Biotherapeutics, Inc. |
Aflibercept formulations and uses thereof
|
|
WO2018215580A1
(en)
|
2017-05-24 |
2018-11-29 |
Formycon Ag |
Method for sterilizing prefilled plastic syringes containing a vegf antagonist
|
|
WO2018217995A1
(en)
|
2017-05-24 |
2018-11-29 |
Formycon Ag |
Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
|
|
US20200171244A1
(en)
|
2017-05-24 |
2020-06-04 |
Sio2 Medical Products, Inc. |
Sterilizable pharmaceutical package for ophthalmic formulations
|
|
TW201904610A
(zh)
|
2017-06-14 |
2019-02-01 |
德商拜耳製藥公司 |
用於治療新生血管型青光眼之非抗體vegf拮抗劑
|
|
WO2019020777A1
(en)
|
2017-07-26 |
2019-01-31 |
Formycon Ag |
LIQUID FORMULATION OF A VEGF ANTAGONIST
|
|
JP7097433B2
(ja)
|
2017-08-17 |
2022-07-07 |
ジャスト－エヴォテック バイオロジックス、インコーポレイテッド |
宿主細胞ガレクチンおよび他の夾雑物からグリコシル化タンパク質を精製する方法
|
|
EP3713591A1
(en)
|
2017-11-20 |
2020-09-30 |
Just-Evotec Biologics, Inc. |
Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
|
|
UA127831C2
(uk)
*
|
2017-11-27 |
2024-01-17 |
4Д Молекьюлар Терапьютикс Інк. |
Капсид аденоасоційованого вірусу та його застосування для інгібування ангіогенезу
|
|
US10973879B2
(en)
|
2017-11-30 |
2021-04-13 |
Regeneron Pharmaceuticals, Inc. |
Use of a VEGF antagonist to treat angiogenic eye disorders
|
|
CN111465848B
(zh)
*
|
2017-12-13 |
2023-11-28 |
里珍纳龙药品有限公司 |
管理层析柱床支架的装置和系统及相关方法
|
|
JP7517988B2
(ja)
|
2018-01-26 |
2024-07-17 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
抗ｖｅｇｆ剤を使用した血管新生障害の治療のための方法および組成物
|
|
US12071476B2
(en)
|
2018-03-02 |
2024-08-27 |
Kodiak Sciences Inc. |
IL-6 antibodies and fusion constructs and conjugates thereof
|
|
IL318714A
(en)
|
2018-05-10 |
2025-03-01 |
Regeneron Pharma |
Formulations that include high concentrations of VEGF receptor fusion protein
|
|
TW202016125A
(zh)
*
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
|
US11519020B2
(en)
|
2018-05-25 |
2022-12-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
|
|
CN111378044B
(zh)
|
2018-12-28 |
2022-07-15 |
长春金赛药业有限责任公司 |
抗体融合蛋白、制备方法及其应用
|
|
EP3969564A1
(en)
|
2019-05-16 |
2022-03-23 |
Formycon AG |
Method for reducing methionine oxidation in recombinant proteins
|
|
JP2022546082A
(ja)
|
2019-09-03 |
2022-11-02 |
アムジエン・インコーポレーテツド |
薬物送達のための注入デバイス及び注入デバイスのためのパッケージ
|
|
EP4031208A1
(en)
|
2019-09-16 |
2022-07-27 |
Amgen Inc. |
Method for external sterilization of drug delivery device
|
|
AU2020364071A1
(en)
|
2019-10-10 |
2022-05-26 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
|
CA3168512A1
(en)
|
2019-11-25 |
2021-06-03 |
Napoleone Ferrara |
Long-acting vegf inhibitors for intraocular neovascularization
|
|
CN114786695A
(zh)
|
2019-12-06 |
2022-07-22 |
瑞泽恩制药公司 |
Vegf微型捕捉体及其使用方法
|
|
TW202128991A
(zh)
|
2019-12-06 |
2021-08-01 |
美商再生元醫藥公司 |
抗ｖｅｇｆ蛋白組成物及其製備方法
|
|
AU2021226754A1
(en)
|
2020-02-24 |
2022-07-07 |
Amgen Inc. |
Containers and systems for use during external sterilization of drug delivery devices
|
|
JP2023525034A
(ja)
|
2020-05-08 |
2023-06-14 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｖｅｇｆトラップおよびミニトラップならびに眼障害およびがんの治療方法
|
|
BR112023022439A2
(pt)
|
2021-04-26 |
2023-12-26 |
Celanese Eva Performance Polymers Llc |
Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
|
|
EP4145456A1
(en)
|
2021-09-06 |
2023-03-08 |
Bayer AG |
Prediction of a change related to a macular fluid
|
|
US20250002557A1
(en)
|
2021-11-24 |
2025-01-02 |
Suzhou Light Ferry Biomed. Co., Ltd |
Multi-specific ligand-binding molecules and applications thereof
|
|
EP4549455A1
(en)
*
|
2022-08-02 |
2025-05-07 |
Panolos Bioscience, Inc. |
Modified fusion protein and use thereof
|
|
CN119584953A
(zh)
|
2022-09-16 |
2025-03-07 |
齐鲁制药有限公司 |
一种稳定的高浓度自缓冲药物组合物
|
|
WO2025033876A1
(ko)
*
|
2023-08-04 |
2025-02-13 |
주식회사 파노로스바이오사이언스 |
변형된 융합 단백질과 scFv의 결합체 및 이의 용도
|
|
WO2025213011A1
(en)
|
2024-04-05 |
2025-10-09 |
Amgen Inc. |
Method of assessing stopper movement in a drug delivery device
|